Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Genprex Inc

GNPX
Current price
2.12 USD -0.14 USD (-6.19%)
Last closed 2.2 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 4 617 140 USD
Yield for 12 month +163.94 %
1Y
3Y
5Y
10Y
15Y
GNPX
21.11.2021 - 28.11.2021

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. Address: 3300 Bee Cave Road, Austin, TX, United States, 78746

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

165 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

+23 154 USD

Last Quarter

Current Year

-15 004 USD

Last Year

-23 830 719 USD

Current Quarter

+19 728 USD

Last Quarter

Key Figures GNPX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -31 060 566 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -108.64 %
PEG Ratio
Return On Equity TTM -207.88 %
Wall Street Target Price 165 USD
Revenue TTM
Book Value 4.99 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -22.56 USD
Diluted Eps TTM -22.56 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics GNPX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History GNPX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:40
Payout Ratio
Last Split Date 02.02.2024
Dividend Date

Stock Valuation GNPX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA 0.0521
Price Book MRQ 0.6904

Financials GNPX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators GNPX

For 52 weeks

2.09 USD 42.4 USD
50 Day MA 2.63 USD
Shares Short Prior Month 49 962
200 Day MA 9.18 USD
Short Ratio 1.47
Shares Short 39 356
Short Percent 2.41 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds


S

SX7EEX

14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics